Cochlear Implants for Hearing Loss

(ACE Trial)

Not currently recruiting at 9 trial locations
LE
Overseen ByLavin Entwisle
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: Cochlear
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 2 JurisdictionsThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests the safety and effectiveness of cochlear implants for adults with bilateral sensorineural hearing loss. The researchers aim to determine if individuals who do not meet the usual qualifications for cochlear implants could still benefit from them. Participants will receive a Cochlear™ Nucleus® implant and undergo speech perception tests at several visits. Suitable candidates have significant hearing loss in both ears but do not qualify for traditional cochlear implants.

As an unphased trial, this study offers a unique opportunity for patients to explore new possibilities for hearing improvement.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinator or your doctor.

What prior data suggests that cochlear implantation is safe for adults with bilateral sensorineural hearing loss?

Research has shown that cochlear implants, including the Cochlear™ Nucleus® System, are generally safe. In one study involving children with these implants, 60 issues occurred in 227 ears, with 14 classified as major. This indicates that about 26% experienced some problems, though serious issues were less frequent. The Cochlear Nucleus system is FDA-approved for specific types of hearing loss, indicating it has been tested and found safe for those cases. These findings suggest that cochlear implants are usually well-tolerated, although, like any medical procedure, some risks exist.12345

Why are researchers excited about this trial?

Unlike other treatments for hearing loss, which often rely on hearing aids to amplify sound, the Cochlear™ Nucleus® System directly stimulates the auditory nerve. This approach bypasses damaged parts of the ear entirely, offering a unique solution for individuals with severe to profound hearing loss who don't benefit from hearing aids. Researchers are excited because this system can provide a more natural hearing experience, potentially improving speech understanding and quality of life for users.

What evidence suggests that cochlear implantation is effective for hearing loss?

Research shows that cochlear implants, such as the Cochlear™ Nucleus® System, work well for individuals with moderate to severe hearing loss. Studies have found that patients understand speech much better after receiving the implant. On average, within three months, users notice significant improvement in recognizing speech compared to before the implant. These benefits persist over time, making the cochlear implant a dependable option. The implant is also considered safe, with studies confirming its successful use across various age groups.16789

Are You a Good Fit for This Trial?

This trial is for adults with bilateral sensorineural hearing loss who don't currently qualify for cochlear implants under FDA guidelines. Participants will be assessed over seven visits after receiving the implant.

Inclusion Criteria

Meets audiometric criteria for the non-implanted contralateral ear: clinically established SNHL with a four frequency PTA at 500, 1000, 2000, & 4000 Hz of >30 dB HL
I have severe hearing loss and struggle to understand words even with a hearing aid.
Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator
See 1 more

Exclusion Criteria

Pregnant or breastfeeding women
Meets current indications on audiometric thresholds for traditional adult CI candidates
I do not have a cochlear nerve or my cochlea is undeveloped.
See 11 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Cochlear Implantation

Participants will be implanted with a commercially approved Cochlear™ Nucleus® implant

1 day
1 visit (in-person)

Post-implantation Assessment

Participants complete speech perception assessments and questionnaires over the course of seven visits

6 months
7 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

36 months

What Are the Treatments Tested in This Trial?

Interventions

  • Cochlear Implantation
Trial Overview The study is testing the Cochlear™ Nucleus® System to see if it's safe and works well in improving hearing for those who have significant hearing loss but aren't eligible for current treatments.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: Cochlear™ Nucleus® SystemExperimental Treatment1 Intervention

Cochlear Implantation is already approved in United States, European Union for the following indications:

🇺🇸
Approved in United States as Cochlear Implant for:
🇪🇺
Approved in European Union as Cochlear Implant for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cochlear

Lead Sponsor

Trials
96
Recruited
6,300+
Headquarters
Sydney, Australia

Dig Howitt

Cochlear

Chief Executive Officer since 2018

BE (Hons), MBA

Michael del Prado

Cochlear

Chief Medical Officer since 2022

MD, MSc, FRACP, FAAHMS, FAICD

Althea Anagnostopoulos Harrington

Collaborator

Trials
2
Recruited
110+

MV Clinical Research, LLC

Collaborator

Trials
2
Recruited
110+

LWB Consulting

Collaborator

Trials
2
Recruited
110+

NAMSA

Collaborator

Trials
55
Recruited
21,500+

Published Research Related to This Trial

In a study of 52 patients with recalled Advanced Bionics cochlear implants, significant hearing performance degradation was observed, particularly linked to issues with the basal-most electrodes of the device.
After revision surgery, patients showed a rapid recovery in hearing performance, reaching peak levels much faster than after their initial implantation, indicating effective outcomes from reimplantation procedures.
Voluntary Field Recall of Advanced Bionics HiRes Cochlear Implants: A Single-Institution Experience.McHugh, CI., Swedenborg, BK., Chen, JX., et al.[2023]
A study analyzing adverse event reports for cochlear implants found that most incidents involved patient injury (16,736 cases) and device malfunction (10,760 cases), highlighting areas for potential safety improvements.
Using machine learning algorithms, researchers achieved high prediction accuracy (up to 88.6%) in identifying the cochlear implant manufacturer and type of adverse event based on the descriptions, suggesting that data analysis can enhance understanding of device performance and safety.
Machine learning for pattern detection in cochlear implant FDA adverse event reports.Crowson, MG., Hamour, A., Lin, V., et al.[2021]
A study of 3,417 cochlear implant recipients over 23 years revealed that the cumulative survival rates (CSRs) for cochlear implants vary significantly between different models and brands, particularly at the 6-year mark.
Common causes of device failure include impact, electronic dysfunction, and leakage, but explant-reimplant procedures are considered safe and effective for addressing these failures.
A review of device failure in more than 23 years of clinical experience of a cochlear implant program with more than 3,400 implantees.Battmer, RD., Linz, B., Lenarz, T.[2022]

Citations

Long-Term Outcomes of Cochlear Implantation in Patients ...Results demonstrate long-term success of patients with high-frequency hearing loss following Hybrid L24 (Cochlear) cochlear implantation.
Cochlear™ Nucleus® systemsNucleus cochlear implant is an effective & long term solution for people with moderate to profound hearing loss. No one match our record for implant ...
Safety and Early Outcomes of Cochlear Implantation ...Improved hearing with cochlear implant use was shown in all outcome measures. Findings reveal that the procedure is safe for infants and that ...
Science Spotlight- Longitudinal outcomes of ...On average, by 3-months postimplant participants exhibited significant increases in speech recognition in the implanted ear compared to their preimplant ...
Evaluating the Clinical- and Cost-Effectiveness of Cochlear ...Hearing loss onset occurred on average at 30 years (SD 21.0), with 12 years (SD 6.2) of CI use. The outcomes show significant improvements in speech ...
Summary of Safety and Effectiveness Data (SSED)The Cochlear Nucleus 24 Cochlear Implant System is indicated for individuals with unilateral hearing loss who meet the following criteria:.
Cochlear™ Nucleus® Reliability ReportsCochlear reliability reporting provides reliability data for the internal (cochlear implant) and external (sound processor) components of our Nucleus Implant ...
Cochlear Implants and Auditory Brainstem ImplantsAccording to FDA criteria, children from 24 months of age with severe-to-profound hearing loss who score less than 30% on open-set speech recognition tests and ...
Cochlear implantation in cochlear nerve deficiencyThe cochlear implant has long proven to be a safe and effective device for facilitating communication in children with congenital SNHL. Although the absence of ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security